What's Happening?
Viridian Therapeutics experienced a significant drop in its stock price, falling by nearly 33% to $18.53 per share, following the release of data from a late-stage study of its investigational antibody for thyroid eye disease. The study met its primary
endpoint by significantly reducing the abnormal bulging of the eyes, known as proptosis, but did not meet investor expectations. The Phase 3 REVEAL-1 study tested two dosing schedules of the subcutaneous anti-IGF1R antibody elegrobart, with results showing a 54% response rate for monthly dosing and 63% for every eight weeks, compared to an 18% response in the placebo group. Despite the positive treatment effect, the placebo-adjusted proptosis responder rates were below the anticipated range of 51%-73%. Analysts from Truist Securities and William Blair noted the potential for regulatory approval and commercialization, despite the weaker-than-expected placebo-adjusted efficacy measures.
Why It's Important?
The outcome of Viridian's study is significant for the biotech industry and investors, as it highlights the challenges of meeting market expectations even when primary endpoints are achieved. The stock decline reflects investor disappointment, which can impact the company's financial stability and future research funding. However, the potential for regulatory approval and commercialization of the first subcutaneous thyroid eye disease drug presents a significant market opportunity. The study's results also underscore the importance of managing placebo effects in clinical trials, which can influence perceived drug efficacy and investor confidence.
What's Next?
Viridian is anticipating a second pivotal readout in thyroid eye disease in the second quarter, with plans to submit a biologics license application in the first quarter of 2027. The company will need to address the concerns raised by the current study's results, particularly the placebo-adjusted efficacy measures, to strengthen its case for regulatory approval. Continued positive safety profiles and further data supporting the drug's efficacy could bolster investor confidence and support the drug's market entry.
